Val­ne­va re­ports more da­ta on Covid-19 vac­cine; Clin­Choice buys a CRO

Val­ne­va pre­sent­ed up­dates on its Covid-19 vac­cine, the first to get the full mar­ket­ing green light in Eu­rope, but the French biotech stopped man­u­fac­tur­ing of it last year be­cause of re­duced or­der vol­ume in the EU.

The com­pa­ny said it has ex­tend­ed the vac­cine’s shelf life by three months, from 18 to 21 months. It al­so said the Eu­ro­pean Med­i­cines Agency’s com­mit­tee gave a pos­i­tive opin­ion for us­ing the vac­cine, VLA2001, as a boost­er dose in adults 18 to 50 years old.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER